Literature DB >> 3289710

Liver transplantation: current concepts.

W J Wall1.   

Abstract

In this decade liver transplantation has been established as the preferred treatment for children and adults with irreversible end-stage liver disease. Biliary atresia in children and nonalcoholic cirrhosis in adults are the most common indications for the procedure. Transplantation currently plays only a minor role in the treatment of hepatic malignant disease. Blood group compatibility between donor and recipient is preferred, but histocompatibility matching (tissue typing) currently has no significant role in the selection of recipients. Approximately 70% of recipients survive for 1 year, and these patients have an excellent prospect of long-term survival. The emerging evidence indicates that the quality of life and rehabilitation of most liver recipients are good. The current success of liver transplantation can be attributed to critical selection of recipients, modern anesthetic and surgical techniques, improved perioperative care, accurate diagnosis of rejection and superior immunosuppression with cyclosporine.

Entities:  

Mesh:

Year:  1988        PMID: 3289710      PMCID: PMC1267982     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  61 in total

1.  Biological effects of cyclosporin A: a new antilymphocytic agent.

Authors:  J F Borel; C Feurer; H U Gubler; H Stähelin
Journal:  Agents Actions       Date:  1976-07

2.  HOMOTRANSPLANTATION OF THE LIVER IN HUMANS.

Authors:  T E STARZL; T L MARCHIORO; K N VONKAULLA; G HERMANN; R S BRITTAIN; W R WADDELL
Journal:  Surg Gynecol Obstet       Date:  1963-12

3.  Transplantation of the liver.

Authors:  R Y Calne
Journal:  Ann Surg       Date:  1978-08       Impact factor: 12.969

4.  Homotransplantation of the liver in a patient with hepatoma and hereditary tyrosinemia.

Authors:  R O Fisch; E R McCabe; D Doeden; L J Koep; J G Kohlhoff; A Silverman; T E Starzl
Journal:  J Pediatr       Date:  1978-10       Impact factor: 4.406

5.  Recovery from "hepatorenal syndrome" after orthotopic liver transplantation.

Authors:  S Iwatsuki; M M Popovtzer; J L Corman; M Ishikawa; C W Putnam; F H Katz; T E Starzl
Journal:  N Engl J Med       Date:  1973-11-29       Impact factor: 91.245

Review 6.  Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction.

Authors:  T E Starzl; M Ishikawa; C W Putnam; K A Porter; R Picache; B S Husberg; C G Halgrimson; G Schroter
Journal:  Transplant Proc       Date:  1974-12       Impact factor: 1.066

7.  Orthotopic liver transplantation for Wilson's disease.

Authors:  R S DuBois; D O Rodgerson; G Martineau; G Shroter; G Giles; J Lilly; C G Halgrimson; T E Starzl; I Sternlieb; I H Scheinberg
Journal:  Lancet       Date:  1971-03-13       Impact factor: 79.321

8.  Orthotopic liver transplantation in ninety-three patients.

Authors:  T E Starzl; K A Porter; C W Putnam; G P Schroter; C G Halgrimson; R Weil; M Hoelscher; H A Reid
Journal:  Surg Gynecol Obstet       Date:  1976-04

9.  Orthotopic liver transplantation: the first 60 patients.

Authors:  R Y Calne; R Williams
Journal:  Br Med J       Date:  1977-02-19

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  2 in total

Review 1.  Liver transplantation (1).

Authors:  T E Starzl; A J Demetris; D Van Thiel
Journal:  N Engl J Med       Date:  1989-10-12       Impact factor: 91.245

2.  Supernatants and lipids from stored red blood cells activate pulmonary microvascular endothelium through the BLT2 receptor and protein kinase C activation.

Authors:  Christopher C Silliman; Marguerite R Kelher; Samina Y Khan; F Bernadette West; Nathan J D McLaughlin; David J Elzi; Kelly England; Jason Bjornsen; Susan A Kuldanek; Anirban Banerjee
Journal:  Transfusion       Date:  2017-09-06       Impact factor: 3.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.